Cyclopharm Balance Sheet Health
Financial Health criteria checks 5/6
Cyclopharm has a total shareholder equity of A$32.3M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$45.9M and A$13.7M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
Interest coverage ratio | n/a |
Cash | AU$11.73m |
Equity | AU$32.26m |
Total liabilities | AU$13.65m |
Total assets | AU$45.91m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CYC's short term assets (A$30.2M) exceed its short term liabilities (A$8.7M).
Long Term Liabilities: CYC's short term assets (A$30.2M) exceed its long term liabilities (A$5.0M).
Debt to Equity History and Analysis
Debt Level: CYC is debt free.
Reducing Debt: CYC has no debt compared to 5 years ago when its debt to equity ratio was 0.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CYC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.